Population pharmacokinetics of Linezolid in children with severe pneumonia

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100041796

Enrollment

Unknown

Registered

2021-01-05

Start date

2021-01-15

Completion date

Unknown

Last updated

2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe pneumonia in children

Interventions

Observation group :Monitor blood drug concentration

Validation group :Monitor blood drug concentration In

Eligibility

Sex/Gender

All

Age

No minimum to 14 Years

Inclusion criteria

Inclusion criteria: 1.Children aged 0-14 years; 2.Meet diagnostic criteria for severe pneumonia (according to the Guidelines for the Diagnosis and Treatment of community-acquired pneumonia in Children (2019 edition).DOI: 10.3760/cma.j.issn.1674-2397.2019.01.002) 3.The standard dose of Linezolid for antiinfective therapy was used. 4.No genetic metabolic diseases and developmental malformations.

Exclusion criteria

Exclusion criteria: 1.Allergic to Linezolid; 2.Receiving other experimental drugs; 3.Clinicians do not believe that children are suitable for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
blood drug concentration;	—

Secondary

Measure	Time frame
Leukocytes, neutrophils and C-reactive protein;Body temperature;	—

Countries

China

Contacts

Public ContactAdong Shen

Beijing Children's Hospital, Capital Medical University

shenad16@hotmail.com+86 13370115087

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026